ERBB2 and gastric neoplasm: Therefore, blocking these HER2-dependent pathways has been considered a promising therapeutic strategy for patients harboring HER2-overexpressing or -amplified cancers; for instance, trastuzumab has been approved for the management of HER2-overexpressing breast and stomach cancers (13, 14).